Sponsor hub

Yale University clinical trial failures

Review 122 stopped clinical trials from Yale University, including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 4 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials122
Likely biological signals4
Shown below100

Dominant stop reasons

OPERATIONAL
76
OTHER/UNKNOWN
40
EFFICACY/FUTILITY
2
REGULATORY
2
SAFETY
2

Notable sponsors

Yale University
122

Related phases

Phase II
52
Phase I
33
Early Phase I
14
Phase IV
12
Unknown
8

Crawlable stopped-trial records

Open Explore

Showing up to 100 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT04415151: Tofacitinib for Treatment of Moderate COVID-19

Phase II COVID-19 Pneumonia trial by Yale University. Stop reason: OPERATIONAL.

Study terminated due to lack of enrollment reflecting the decrease in number of COVID infections. There were no safety and/or efficacy concerns involved in the decision to stop enrollment.